Cancer-Focused Biopharma Co. Tallies $60M Funding Round
Biopharmaceutical firm FLX Bio Inc. on Thursday said its latest funding round brought in $60 million from new and existing investors that will help the company advance a leading treatment through...To view the full article, register now.
Already a subscriber? Click here to view full article